Literature DB >> 23864129

Angiogenesis inhibition for glioblastoma at the edge: beyond AVAGlio and RTOG 0825.

Michael Weller, W K Alfred Yung.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23864129      PMCID： PMC3714162          DOI： 10.1093/neuonc/not106

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  21 in total

1.  Culturally and linguistically diverse patient participation in glioma research.

Authors:  Zarnie Lwin; Alexander Broom; Rasha Cosman; Ann Livingstone; Kate Sawkins; Phillip Good; Emma Kirby; Eng-Siew Koh; Elizabeth Hovey
Journal:  Neurooncol Pract       Date:  2014-06-25

2.  Large volume re-irradiation with bevacizumab is a feasible salvage option for patients with refractory high-grade glioma.

Authors:  Michael Back; Cecelia E Gzell; Marina Kastelan; Linxin Guo; Helen R Wheeler
Journal:  Neurooncol Pract       Date:  2014-12-15

3.  Voxel-based evidence of perfusion normalization in glioblastoma patients included in a phase I-II trial of radiotherapy/tipifarnib combination.

Authors:  Soléakhéna Ken; Alexandra Deviers; Thomas Filleron; Isabelle Catalaa; Jean-Albert Lotterie; Jonathan Khalifa; Vincent Lubrano; Isabelle Berry; Patrice Péran; Pierre Celsis; Elizabeth Cohen-Jonathan Moyal; Anne Laprie
Journal:  J Neurooncol       Date:  2015-07-19       Impact factor: 4.130

4.  Is deferred use of bevacizumab for glioblastoma associated with prolonged survival?

Authors:  Quintino Giorgio D'Alessandris; Gabriele Capo; Roberto Pallini
Journal:  Neuro Oncol       Date:  2014-07-22       Impact factor: 12.300

Review 5.  Vessel caliber--a potential MRI biomarker of tumour response in clinical trials.

Authors:  Kyrre E Emblem; Christian T Farrar; Elizabeth R Gerstner; Tracy T Batchelor; Ronald J H Borra; Bruce R Rosen; A Gregory Sorensen; Rakesh K Jain
Journal:  Nat Rev Clin Oncol       Date:  2014-08-12       Impact factor: 66.675

Review 6.  Rindopepimut: a promising immunotherapeutic for the treatment of glioblastoma multiforme.

Authors:  Adam M Swartz; Qi-Jing Li; John H Sampson
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

7.  CXCL12 secreted from glioma stem cells regulates their proliferation.

Authors:  Youji Uemae; Eiichi Ishikawa; Satoru Osuka; Masahide Matsuda; Noriaki Sakamoto; Shingo Takano; Kei Nakai; Tetsuya Yamamoto; Akira Matsumura
Journal:  J Neurooncol       Date:  2014-01-19       Impact factor: 4.130

Review 8.  Treatment-related changes in glioblastoma: a review on the controversies in response assessment criteria and the concepts of true progression, pseudoprogression, pseudoresponse and radionecrosis.

Authors:  P D Delgado-López; E Riñones-Mena; E M Corrales-García
Journal:  Clin Transl Oncol       Date:  2017-12-07       Impact factor: 3.405

Review 9.  Targeting adaptive glioblastoma: an overview of proliferation and invasion.

Authors:  Qian Xie; Sandeep Mittal; Michael E Berens
Journal:  Neuro Oncol       Date:  2014-07-30       Impact factor: 12.300

10.  [Interdisciplinary neuro-oncology: part 2: systemic therapy of primary brain tumors].

Authors:  G Tabatabai; E Hattingen; J Schlegel; W Stummer; U Schlegel
Journal:  Nervenarzt       Date:  2014-08       Impact factor: 1.214
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.